These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633 [TBL] [Abstract][Full Text] [Related]
3. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104 [TBL] [Abstract][Full Text] [Related]
4. [Thrombosis in myeloproliferative neoplasms]. Asakura H Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703 [TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Iványi JL; Marton E; Plander M Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365 [TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Reikvam H; Tiu RV Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463 [TBL] [Abstract][Full Text] [Related]
7. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562 [TBL] [Abstract][Full Text] [Related]
8. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Sankar K; Stein BL; Rampal RK Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487 [TBL] [Abstract][Full Text] [Related]
9. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568 [TBL] [Abstract][Full Text] [Related]
10. Thrombosis among 1537 patients with JAK2 Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332 [TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms]. Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms. Wen S; Zhang W; Fei Y; Guan K; Zhao H; Song P; Ye X; Pan Y J Clin Neurosci; 2024 Jul; 125():159-166. PubMed ID: 38815302 [TBL] [Abstract][Full Text] [Related]
13. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
14. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms. Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945 [TBL] [Abstract][Full Text] [Related]
15. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms]. Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698 [TBL] [Abstract][Full Text] [Related]
16. Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? Vianello F; Cella G; Osto E; Ballin A; Famoso G; Tellatin S; Iliceto S; Cucchini U; Saggiorato G; Omenetto E; Tona F Am J Hematol; 2015 Feb; 90(2):109-13. PubMed ID: 25352381 [TBL] [Abstract][Full Text] [Related]
17. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989 [TBL] [Abstract][Full Text] [Related]
18. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. Deadmond MA; Smith-Gagen JA J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903 [TBL] [Abstract][Full Text] [Related]
19. The spectrum of JAK2-positive myeloproliferative neoplasms. Kiladjian JJ Hematology Am Soc Hematol Educ Program; 2012; 2012():561-6. PubMed ID: 23233635 [TBL] [Abstract][Full Text] [Related]
20. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]